A recently conducted study has revealed an intriguing fact about tumour growth. The genetic sequencing of an entire prostate cancer cell genome has been able to find out things that may soon revolutionize cancer treatment.

A better understanding of the cell may soon help in the development of drugs that may provide treatments never seen before. Apparently, scientists might be able to target specific regions of a tumour in order to ensure that the cancerous body does not spread to other parts and that it’s negating effects are reduced to the minimal.

The study was led by an assistant professor at the Memorial Sloan-Kettering Cancer Center in New York, Michael Berger. Talking about the research, Berger informed that additional studies and further research in the subject will help people in better understanding between benign and prostate cancers. An improved diagnosis to distinguish between the two will also help in understanding the type of treatment that is required.

The research has already appeared in the 10th February pullout of the publication known as Nature. It was successful only because of the concerted efforts pitched in by researchers at the Broad Institute, Dean-Farber Cancer Institute and Well Cornell.

DNA rearrangements were looked to be important for people suffering from blood cancer. However, recent research work has reported that genome sequencing might even prove to be beneficial for those suffering from breast and prostate cancer.